148 related articles for article (PubMed ID: 12124170)
1. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.
Sawyers CL
Cancer Cell; 2002 Jun; 1(5):413-5. PubMed ID: 12124170
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
Weisberg E; Boulton C; Kelly LM; Manley P; Fabbro D; Meyer T; Gilliland DG; Griffin JD
Cancer Cell; 2002 Jun; 1(5):433-43. PubMed ID: 12124173
[TBL] [Abstract][Full Text] [Related]
3. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Sattler M; Scheijen B; Weisberg E; Griffin JD
Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
[TBL] [Abstract][Full Text] [Related]
4. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571.
Böhmer FD; Karagyozov L; Uecker A; Serve H; Botzki A; Mahboobi S; Dove S
J Biol Chem; 2003 Feb; 278(7):5148-55. PubMed ID: 12435730
[TBL] [Abstract][Full Text] [Related]
5. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
Kelly LM; Yu JC; Boulton CL; Apatira M; Li J; Sullivan CM; Williams I; Amaral SM; Curley DP; Duclos N; Neuberg D; Scarborough RM; Pandey A; Hollenbach S; Abe K; Lokker NA; Gilliland DG; Giese NA
Cancer Cell; 2002 Jun; 1(5):421-32. PubMed ID: 12124172
[TBL] [Abstract][Full Text] [Related]
6. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.
Levis M; Tse KF; Smith BD; Garrett E; Small D
Blood; 2001 Aug; 98(3):885-7. PubMed ID: 11468194
[TBL] [Abstract][Full Text] [Related]
7. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Cools J; Mentens N; Furet P; Fabbro D; Clark JJ; Griffin JD; Marynen P; Gilliland DG
Cancer Res; 2004 Sep; 64(18):6385-9. PubMed ID: 15374944
[TBL] [Abstract][Full Text] [Related]
8. FLT3 Inhibitors in the Treatment of AML.
Gilliland DG
Clin Adv Hematol Oncol; 2004 Nov; 2(11):708-10. PubMed ID: 16163256
[No Abstract] [Full Text] [Related]
9. FLT3 as a therapeutic target in childhood acute leukemia.
Stubbs MC; Armstrong SA
Curr Drug Targets; 2007 Jun; 8(6):703-14. PubMed ID: 17584026
[TBL] [Abstract][Full Text] [Related]
10. Small molecule FLT3 tyrosine kinase inhibitors.
Levis M; Small D
Curr Pharm Des; 2004; 10(11):1183-93. PubMed ID: 15078134
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
Sternberg DW; Licht JD
Curr Opin Hematol; 2005 Jan; 12(1):7-13. PubMed ID: 15604885
[TBL] [Abstract][Full Text] [Related]
12. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy.
Naoe T; Kiyoe H; Yamamoto Y; Minami Y; Yamamoto K; Ueda R; Saito H
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S27-30. PubMed ID: 11587362
[TBL] [Abstract][Full Text] [Related]
13. FLT3 inhibition as tailored therapy for acute myeloid leukemia.
Martinelli G; Piccaluga PP; Lo Coco F
Haematologica; 2003 Jan; 88(1):4-8. PubMed ID: 12551818
[No Abstract] [Full Text] [Related]
14. FLT3: ITDoes matter in leukemia.
Levis M; Small D
Leukemia; 2003 Sep; 17(9):1738-52. PubMed ID: 12970773
[TBL] [Abstract][Full Text] [Related]
15. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
[TBL] [Abstract][Full Text] [Related]
16. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
[TBL] [Abstract][Full Text] [Related]
17. FLT3 tyrosine kinase as a target in acute leukemias.
Griffin JD
Hematol J; 2004; 5 Suppl 3():S188-90. PubMed ID: 15190306
[No Abstract] [Full Text] [Related]
18. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Smith BD; Levis M; Beran M; Giles F; Kantarjian H; Berg K; Murphy KM; Dauses T; Allebach J; Small D
Blood; 2004 May; 103(10):3669-76. PubMed ID: 14726387
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of the flt3-inhibitor su5614 and standard cytotoxic agents in tumour cells from patients with wild type and mutated flt3 acute myeloid leukaemia.
Aleskog A; Höglund M; Pettersson J; Hermansson M; Larsson R; Lindhagen E
Leuk Res; 2005 Sep; 29(9):1079-81. PubMed ID: 16038735
[TBL] [Abstract][Full Text] [Related]
20. Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects.
Heinrich MC
Mini Rev Med Chem; 2004 Mar; 4(3):255-71. PubMed ID: 15032673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
